Prospective Assessment of Serum Lipid Alterations in Chronic Hepatitis C Patients Treated with Direct Acting Antivirals: Insights Six Months Post Sustained Virological Response
Authors:
- Oana KoppandiOana Koppandi
- Dana IovănescuDIDana Iovănescu
- Bogdan MiuțescuBMBogdan Miuțescu
- Alexandru Cătălin MotofeleaAMAlexandru Cătălin Motofelea
- Oana Maria JigăuOJOana Maria Jigău
- Andreea Iulia PapoiAPAndreea Iulia Papoi
- Călin BurciuCBCălin Burciu
- Eyad GadourEyad Gadour
- Deiana VuleticiDVDeiana Vuletici
- Eftimie MiuțescuEMEftimie Miuțescu
Open Access
Abstract
Background and Objectives: Chronic hepatitis C virus (HCV) infection is intricately linked with dysregulation of lipid metabolism. In particular, cholesterol plays a crucial role in HCV replication. Direct-acting antiviral agents (DAAs) therapy has revolutionized the hepatitis C treatment landscape, achieving high rates of sustained virological response (SVR). However, viral clearance comes with some alterations in lipid-related markers. This prospective study aimed to evaluate the impact of HCV clearance on lipid homeostasis and non-invasive liver fibrosis markers in hepatitis C patients treated with DAAs. Material and Methods: Fifty-two patients with varying degrees of fibrosis treated with DAAs therapy were evaluated at baseline and 24 weeks post-SVR. Lipid profiles and non-invasive liver fibrosis markers were assessed. Results: Our findings revealed an increase in total cholesterol, triglyceride, and LDLc (low-density lipoprotein cholesterol) levels at 24 weeks post-SVR, alongside an improvement in serum liver enzymes. Although improvements in liver stiffness were observed in non-invasive tests, there was an increase in lipid-related markers post-SVR. Conclusions: This suggests a potential increased cardiovascular risk despite improvements in liver function and fibrosis, highlighting the necessity for statin therapy in some cases and extended follow-ups for these patients. These findings underscore the importance of closely monitoring lipid profiles in chronic hepatitis C patients post-SVR, as well as the potential need for statin therapy to mitigate cardiovascular risk. Additionally, extended follow-up is essential to assess long-term outcomes and ensure the optimal management of these patients.Keywords
This publication has 18 references indexed in Scilit:
- Lipid profile changes after direct acting antiviral treatment in different genotypes of chronic hepatitis C virus-infected patientsAdvances in Digestive Medicine, 2021
- Serum lipid profile in HCV patients treated with direct-acting antivirals: a systematic review and meta-analysisScientific Reports, 2021
- Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antiviralsJournal of Hepatology, 2020
- Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology CommissionThe Lancet Gastroenterology & Hepatology, 2019
- INCREASE OF LIPIDS DURING HCV TREATMENT: VIRUS ACTION OR MEDICATION?Arquivos de Gastroenterologia, 2018
- New Epidemiologic Data Regarding Hepatitis C Virus Infection in RomaniaJournal of Gastrointestinal and Liver Diseases, 2017
- Rapid Increase in Serum Low-Density Lipoprotein Cholesterol Concentration during Hepatitis C Interferon-Free TreatmentPLOS ONE, 2016
- Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis‐4 score and aspartate aminotransferase‐platelet ratio indexLiver International, 2016
- Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1–infected patientsHepatology, 2014
- Hepatitis C Virus Infection and Its Clearance Alter Circulating LipidsHepatology, 2009